STOCK TITAN
  1. Home
  2. Sec-filings
  3. QURE
  4. [Form 4] uniQure N.V. Insider Trading Activity

QURE director exercises options and sells shares under Rule 10b5-1

Filing Impact
(High)
Filing Sentiment
(Negative)
Form Type
4

Rhea-AI Filing Summary

uniQure N.V. (QURE) disclosed that a director executed option exercises and same‑day sales on 11/04/2025 pursuant to a Rule 10b5‑1 trading plan adopted on June 16, 2025.

The director exercised 10,000 options at $7.37, 11,000 at $5.37, and 17,810 at $14.08, then sold equivalent ordinary shares at weighted average prices of $30.36, $30.34, and $30.33, respectively. Following these transactions, the director beneficially owned 20,439 ordinary shares, held directly.

Positive

  • None.

Negative

  • None.
Insider Kaye Jack
Role Director
Sold 38,810 shs ($1.18M)
Type Security Shares Price Value
Exercise Stock Option (Right to Buy) 10,000 $0.00 --
Exercise Stock Option (Right to Buy) 11,000 $0.00 --
Exercise Stock Option (Right to Buy) 17,810 $0.00 --
Exercise Ordinary Shares 10,000 $7.37 $74K
Sale Ordinary Shares 10,000 $30.36 $304K
Exercise Ordinary Shares 11,000 $5.37 $59K
Sale Ordinary Shares 11,000 $30.34 $334K
Exercise Ordinary Shares 17,810 $14.08 $251K
Sale Ordinary Shares 17,810 $30.33 $540K
Holdings After Transaction: Stock Option (Right to Buy) — 0 shares (Direct); Ordinary Shares — 30,439 shares (Direct)
Footnotes (1)
  1. The transactions reported herein were effected pursuant to a sales plan adopted by the Reporting Person on June 16, 2025 and intended to comply with Rule 10b5-1 under the Securities Exchange Act of 1934. The price reported in Column 4 is a weighted average price. The shares were sold in multiple transactions at prices ranging from $30.20 to $30.79. The Reporting Person undertakes to provide to the Issuer, any shareholder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote. The price reported in Column 4 is a weighted average price. The shares were sold in multiple transactions at prices ranging from $30.16 to $30.75. The Reporting Person undertakes to provide to the Issuer, any shareholder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote. The price reported in Column 4 is a weighted average price. The shares were sold in multiple transactions at prices ranging from $30.00 to $30.90. The Reporting Person undertakes to provide to the Issuer, any shareholder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote. The Stock Option vested 25% on June 30, 2018 and 6.25% quarterly thereafter. The Stock Option vested in full on January 27, 2018. The Stock Option vested in full on June 15, 2023.
Form 4 Insider Transactions: What Each Field Means →
SEC Form 4
FORM 4 UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940
OMB APPROVAL
OMB Number: 3235-0287
Estimated average burden
hours per response: 0.5
Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).
X
 Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.
1. Name and Address of Reporting Person*
Kaye Jack
(Last) (First) (Middle)
C/O UNIQURE N.V.
PAASHEUVELWEG 25A
(Street)
AMSTERDAM P7 11058BP
(City) (State) (Zip)
2. Issuer Name and Ticker or Trading Symbol
uniQure N.V. [ QURE ] 		5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)
X Director 10% Owner
Officer (give title below) Other (specify below)
3. Date of Earliest Transaction (Month/Day/Year)
11/04/2025
4. If Amendment, Date of Original Filed (Month/Day/Year)
 6. Individual or Joint/Group Filing (Check Applicable Line)
X Form filed by One Reporting Person
Form filed by More than One Reporting Person
Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3) 2. Transaction Date (Month/Day/Year) 2A. Deemed Execution Date, if any (Month/Day/Year) 3. Transaction Code (Instr. 8) 4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5) 5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4) 6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4) 7. Nature of Indirect Beneficial Ownership (Instr. 4)
Code V Amount (A) or (D) Price
Ordinary Shares 11/04/2025 M(1) 10,000 A $7.37 30,439 D
Ordinary Shares 11/04/2025 S(1) 10,000 D $30.36(2) 20,439 D
Ordinary Shares 11/04/2025 M(1) 11,000 A $5.37 31,439 D
Ordinary Shares 11/04/2025 S(1) 11,000 D $30.34(3) 20,439 D
Ordinary Shares 11/04/2025 M(1) 17,810 A $14.08 38,249 D
Ordinary Shares 11/04/2025 S(1) 17,810 D $30.33(4) 20,439 D
Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned
(e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3) 2. Conversion or Exercise Price of Derivative Security 3. Transaction Date (Month/Day/Year) 3A. Deemed Execution Date, if any (Month/Day/Year) 4. Transaction Code (Instr. 8) 5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5) 6. Date Exercisable and Expiration Date (Month/Day/Year) 7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4) 8. Price of Derivative Security (Instr. 5) 9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4) 10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4) 11. Nature of Indirect Beneficial Ownership (Instr. 4)
Code V (A) (D) Date Exercisable Expiration Date Title Amount or Number of Shares
Stock Option (Right to Buy) $7.37 11/04/2025 M(1) 10,000 (5) 06/29/2027 Ordinary Shares 10,000 $0 0 D
Stock Option (Right to Buy) $5.37 11/04/2025 M(1) 11,000 (6) 01/27/2027 Ordinary Shares 11,000 $0 0 D
Stock Option (Right to Buy) $14.08 11/04/2025 M(1) 17,810 (7) 06/15/2032 Ordinary Shares 17,810 $0 0 D
Explanation of Responses:
1. The transactions reported herein were effected pursuant to a sales plan adopted by the Reporting Person on June 16, 2025 and intended to comply with Rule 10b5-1 under the Securities Exchange Act of 1934.
2. The price reported in Column 4 is a weighted average price. The shares were sold in multiple transactions at prices ranging from $30.20 to $30.79. The Reporting Person undertakes to provide to the Issuer, any shareholder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote.
3. The price reported in Column 4 is a weighted average price. The shares were sold in multiple transactions at prices ranging from $30.16 to $30.75. The Reporting Person undertakes to provide to the Issuer, any shareholder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote.
4. The price reported in Column 4 is a weighted average price. The shares were sold in multiple transactions at prices ranging from $30.00 to $30.90. The Reporting Person undertakes to provide to the Issuer, any shareholder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote.
5. The Stock Option vested 25% on June 30, 2018 and 6.25% quarterly thereafter.
6. The Stock Option vested in full on January 27, 2018.
7. The Stock Option vested in full on June 15, 2023.
/s/ Christian Klemt, Attorney-in-Fact 11/06/2025
** Signature of Reporting Person Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.

Source: View Original Filing on SEC EDGAR

FAQ

What did uniQure (QURE) report in this Form 4?

A director exercised stock options and sold the resulting ordinary shares under a Rule 10b5-1 plan.

When did the QURE transactions occur?

All transactions took place on 11/04/2025.

How many options were exercised and at what prices?

Options for 10,000 shares at $7.37, 11,000 at $5.37, and 17,810 at $14.08 were exercised.

At what prices were the shares sold?

Shares were sold at weighted averages of $30.36, $30.34, and $30.33; sales occurred in multiple trades within disclosed ranges.

How many QURE shares does the director own after these trades?

The director beneficially owns 20,439 ordinary shares directly after the reported transactions.

Was a Rule 10b5-1 trading plan used?

Yes. The plan was adopted on June 16, 2025 and the transactions were effected pursuant to it.

What transaction codes appeared on the Form 4?

Code M (option exercise) and code S (sale) were reported.